Powell Andrew Kenneth William 4
4 · Aclaris Therapeutics, Inc. · Filed Jun 6, 2022
Insider Transaction Report
Form 4
Powell Andrew Kenneth William
Director
Transactions
- Exercise/Conversion
Common Stock
2022-06-03+3,356→ 13,856 total - Award
Stock Option (Right to Buy)
2022-06-02+15,750→ 15,750 totalExercise: $14.48Exp: 2032-06-01→ Common Stock (15,750 underlying) - Gift
Common Stock
2022-05-16−709→ 10,500 total - Exercise/Conversion
Restricted Stock Units
2022-06-03−3,356→ 0 total→ Common Stock (3,356 underlying) - Award
Restricted Stock Units
2022-06-02+4,507→ 4,507 total→ Common Stock (4,507 underlying)
Footnotes (5)
- [F1]Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- [F2]This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy.
- [F3]The shares subject to this option will vest in twelve equal monthly installments commencing July 2, 2022, subject to Reporting Person's continuous service through each such date.
- [F4]The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date.
- [F5]The shares underlying these restricted stock units vested on June 3, 2022.